FIELD: medicine, oncology, pharmacology, pharmacy.
SUBSTANCE: invention relates to a preparation used in the simultaneous, separate or time-distributed therapeutic using in cancer treatment. The preparation comprises inhibitor of signals transduction of heterotrimeric G proteins chosen from 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-methylphenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine, 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine and at least one additional cytostatic agent also. Proposed preparations possess the enhanced effectiveness.
EFFECT: enhanced and valuable medicinal properties of preparation.
6 cl, 5 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
USING DERIVATIVES OF CYSTEINE FOR PREPARING MEDICINAL AGENT DESIGNATED FOR TREATMENT OF PATHOLOGY ARISING AS RESULT OF FORMATION OF HETEROTRIMERIC PROTEIN G | 1999 |
|
RU2268889C2 |
DERIVATIVES OF IMIDAZOLE AS INHIBITORS OF PRENYL TRANSFERASE, PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT BASED ON THEREOF | 1999 |
|
RU2241712C9 |
ANELLATED CABAMOYLAZAHETEROCYCLES, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PREPARING | 2005 |
|
RU2281947C1 |
PRODUCT COMPRISING AT LEAST ONE SUBSTANCE INHIBITING ACTIVITY OF NO-SYNTHASE IN COMBINATION WITH AT LEAST ONE SUBSTANCE INHIBITING ACTIVITY OF PHOSPHOLIPASE A | 2000 |
|
RU2256465C2 |
AMINOTETRALINE DERIVATIVES CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS AND USING THEM IN THERAPY | 2010 |
|
RU2546649C2 |
HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
IMIDAZOPYRAZINE OR IMIDAZODIAZEPINE DERIVATIVES, ACTIVE WITH RESPECT TO RECEPTOR CB2 | 2008 |
|
RU2540074C2 |
NOVEL DERIVATIVES OF BENZIMIDAZOLE AND THEIR USING AS MEDICAMENTS | 2002 |
|
RU2294326C2 |
DERIVATIVES OF FIVE-MEMBER HETEROCYCLES, METHOD OF PRODUCTION AND USE THEREOF AS MEDICINAL AGENTS | 2000 |
|
RU2380362C2 |
FIVE-MEROUS HETEROCYCLE DERIVATIVES, METHOD FOR PREPARING AND USING THEM AS THERAPEUTIC AGENTS | 2009 |
|
RU2530882C2 |
Authors
Dates
2007-05-10—Published
2000-11-08—Filed